Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:42:18.317Z.
Calculation as of: 2026-10-06T15:42:18.317Z.
Quote observation: 2026-10-06T15:38:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 581b2fbaae035830ca35d06372124b56c7048e0f0ab23ef832a371d1053372ba
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.81M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | 107.67 | 20.09 | 7.30 | 5.50 |
| Optimi Health Corp. (OPTH)vs › | $13.44M | 108.20 | 130.06 | 643.92 | 552.45 |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.37M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $13.01M | 0.35 | 0.98 | 1.40 | 2.22 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.04M | 1.98 | 3.04 | 3.04 | 3.04 |
| Passage Bio, Inc. (PASG)vs › | $13.45M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.37M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $13.27M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.02M | N/A | 47196.93 | 20633.59 | 21825.74 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
